Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Ovarian Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
46 drugs · 161 active trials
11 drugs · 195 active trials
5 drugs · 126 active trials
Data updated 10 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Regorafenib | Phase 2 | Phase 2 | 1 | 1 | 0 | 4 | 0 | — | — | 2014-12 |
| Tislelizumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Apr 1, 2021 |
| Tivozanib | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | Jun 6, 2013 |
| Bendamustine | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | 2009-02 |
| Entrectinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Nov 19, 2015 |
| Erdafitinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Imiquimod | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2008-05 |
| Nilotinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Oct 13, 2022 |
| Osimertinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Ramucirumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2008-08 |
| Sintilimab | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Dec 23, 2020 |
| Adebrelimab | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Mar 18, 2025 |
| Afatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Anti-VEGF Monoclonal Antibody | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Sep 24, 2026 |
| Belzutifan | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Dec 20, 2024 |
| Crizotinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Dabrafenib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Dordaviprone | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jan 21, 2020 |
| Fasudil | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | 2025-04 |
| Fexagratinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Fruquintinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Jul 1, 2025 |
| Imlunestrant | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Dec 1, 2026 |
| Inavolisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Oct 7, 2021 |
| Larotrectinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Paclitaxel Liposome | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jun 20, 2025 |
| Rezatapopt | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Oct 29, 2020 |
| Sotorasib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Apr 7, 2023 |
| Taselisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Tazemetostat | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | May 1, 2019 |
| Telmisartan | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jan 21, 2026 |
| Trastuzumab Deruxtecan | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Nov 12, 2020 |
| Tretinoin | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Dec 22, 2025 |
| Zanidatamab | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jan 14, 2025 |
| Temozolomide | Phase 2 | Phase 2 | 0 | 0 | 0 | 9 | 0 | — | — | 1998-09 |
| Thiotepa | Phase 2 | Phase 2 | 0 | 0 | 0 | 9 | 0 | — | — | 1992-10 |
| Bortezomib | Phase 2 | Phase 2 | 0 | 0 | 0 | 7 | 0 | — | — | 2001-05 |
| Everolimus | Phase 2 | Phase 2 | 0 | 0 | 0 | 7 | 0 | — | — | 2010-09 |
| Imatinib Mesylate | Phase 2 | Phase 2 | 0 | 0 | 0 | 7 | 0 | — | — | 2000-08 |
| Temsirolimus | Phase 2 | Phase 2 | 0 | 0 | 0 | 7 | 0 | — | — | 2007-02 |
| Belinostat | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 2005-08 |
| Gefitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 2001-08 |
| Lapatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 2005-05 |
| Sorafenib Tosylate | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 2004-08 |
| Catumaxomab | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2006-09 |
| Metformin | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | Feb 25, 2015 |
| Nintedanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2011-11 |
| Sirolimus | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2012-03 |
| Vinorelbine | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 1999-12 |
| Alemtuzumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2005-01 |
| Alisertib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Mar 23, 2009 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.